SCHEMBL25753394

SCHEMBL25753394

Cc1c(N)ccc[n+]1C

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2495381 0.74
SCHEMBL13734493 0.73
Fluoride Ion SCHEMBL12474470 0.72 KMT2A (0.38)
Bromide SCHEMBL28737975 0.72 KMT2A (0.38)
Hydrochloric Acid SCHEMBL6267344 0.72 KMT2A (0.38)
Bromide SCHEMBL30517303 0.72 KMT2A (0.38)
Bromide SCHEMBL8748601 0.72 KMT2A (0.38)
Iodide SCHEMBL10809229 0.71 CYP3A4 (0.39)
Hydrochloric Acid SCHEMBL4093688 0.71 CYP3A4 (0.41)
SCHEMBL6403148 0.69 ALDH1A1 (0.48)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203044-A1 PYRAZOLO[1,5-D][1,2,4]TRIAZINE-5(4H)-ACETAMIDES AS INHIBITORS OF THE NLRP3 INFLAMMASOME JANSSEN PHARMACEUTICA NV (BE) 2023-06-29 US disclosed
CN-110022875-A Therapeutic inhibiting compound 莱福斯希医药公司 2019-07-16 CN disclosed
CN-107072985-A Therapeutic inhibiting compound 莱福斯希医药公司 2017-08-18 CN disclosed